Human plasma enhances the infectivity of primary human immunodeficiency virus type 1 isolates in peripheral blood mononuclear cells and monocyte-derived macrophages

Wu, Suh-Chin; Spouge, John L.; Conley, S; Tsai, Wen-Po; Merges, Michael; Nara, Peter L.

doi:10.1128/jvi.69.10.6054-6062.1995

Cited by 32 publications

(11 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In sera from monkeys infected with SIVmac251, ADE could be demonstrated, while this was not observed in macaques that were vaccinated with HIV-2 envelope preparations [61]. Furthermore, it has been reported that plasma obtained from SIV-mac251 infected animals enhanced SIVmac infection of a human CD4 + cell line, which was dependent on the presence of complement [62], in a manner similar to the complement-mediated ADE activity observed with HIV-positive human sera in in vitro experiments described above [46,63,64].…”

Section: Antibody-dependent Enhancement Of Lentivirus Entrymentioning

confidence: 66%

Vaccine-induced enhancement of viral infections

Huisman

Martina

Rimmelzwaan

et al. 2009

Vaccine

162

134

View full text Add to dashboard Cite

Examples of vaccine-induced enhancement of susceptibility to virus infection or of aberrant viral pathogenesis have been documented for infections by members of different virus families. Several mechanisms, many of which still are poorly understood, are at the basis of this phenomenon. Vaccine development for lentivirus infections in general, and for HIV/AIDS in particular, has been little successful. Certain experimental lentiviral vaccines even proved to be counterproductive: they rendered vaccinated subjects more susceptible to infection rather than protecting them. For vaccine-induced enhanced susceptibility to infection with certain viruses like feline coronavirus, Dengue virus, and feline immunodeficiency virus, it has been shown that antibody-dependent enhancement (ADE) plays an important role. Other mechanisms may, either in the absence of or in combination with ADE, be involved. Consequently, vaccine-induced enhancement has been a major stumble block in the development of certain flavi-, corona-, paramyxo-, and lentivirus vaccines. Also recent failures in the development of a vaccine against HIV may at least in part be attributed to induction of enhanced susceptibility to infection. There may well be a delicate balance between the induction of protective immunity on the one hand and the induction of enhanced susceptibility on the other. The present paper reviews the currently known mechanisms of vaccine-induced enhancement of susceptibility to virus infection or of aberrant viral pathogenesis.

show abstract

Section: Antibody-dependent Enhancement Of Lentivirus Entrymentioning

confidence: 66%

Vaccine-induced enhancement of viral infections

Huisman

Martina

Rimmelzwaan

et al. 2009

Vaccine

162

134

View full text Add to dashboard Cite

show abstract

“…The plasma for the bioassays was collected by using heparin as an anticoagulant, while EDTA was used in this study. With HIV-1, EDTA has been shown to protect viral RNA from degradation (11,13,19,21,25), while heparin maintained viral infectivity (7,43).…”

Section: Discussionmentioning

confidence: 99%

“…The use of a curve for single-standard RNA reduced the levels of variation be-VOL. 43,2005 QUANTIFICATION OF JEMBRANA DISEASE VIRUS LOAD 5575 on April 30, 2020 by guest http://jcm.asm.org/ tween experiments and standardized the quantification of the RNA.…”

Section: Sensitivity and Dynamic Range Of The Taqman Real-time Rt-pcrmentioning

confidence: 99%

TaqMan Real-Time Reverse Transcription-PCR and JDVp26 Antigen Capture Enzyme-Linked Immunosorbent Assay To Quantify Jembrana Disease Virus Load during the Acute Phase of In Vivo Infection

et al. 2005

View full text Add to dashboard Cite

Jembrana disease virus (JDV) is an acutely pathogenic lentivirus that affects Bali cattle in Indonesia. The inability to propagate the virus in vitro has made it difficult to quantitate JDV and determine the kinetics of virus replication during the acute phase of the disease process. We report for the first time two techniques that enable quantification of the virus and the use of these techniques to quantify the virus load during the acute phase of the disease process. A one-step JDV pol TaqMan Jembrana disease virus (JDV) causes an atypical lentivirus infection that results in an acute severe disease that affects Bali cattle (Bos javanicus) within Indonesia (4,20,36). JDV has a short incubation period of 4 to 12 days, and the disease is characterized by a febrile response, lethargy, anorexia, leukopenia, and enlargement of superficial lymph nodes and a mortality rate of about 17% (36). The majority of animals develop detectable antibodies to the virus only 6 weeks or more after recovery from the acute phase of the disease (17, 41). Surviving animals are resistant to reinfection, remain infectious for at least 2 years, and do not appear to suffer further episodes of disease (35).Attempts to cultivate JDV in vitro have been unsuccessful (42), and this has restricted the development of assays for the quantification of infectious virus. A series of animal bioassay experiments reported by Soeharsono et al. (35) provide the only data available regarding virus replication during the acute phase of disease process. These studies revealed that there was a high titer of infectious virus in plasma of about 10 8 50% cattle infectious doses (ID 50 )/ml during the acute febrile period, decreasing to low levels and persisting at low levels in recovered animals. A strong correlation between the initial dose of virus in a sample and the time between infection and onset of the acute febrile disease period was observed (35). Although this bioassay provided a method for titration of infectious virus, it was time-consuming and expensive. Techniques that do not require the use of animals for assay of virus are needed for further studies on the kinetics of virus replication during the acute phase of the disease process and for understanding the persistence of virus in recovered animals. Additionally, the development of an inactivated virus vaccine for JDV which relied on clinical observations to determine the efficacy of different vaccine formulations has been reported (16), and further studies of vaccine development would be greatly facilitated by the capacity to quantify the virus load in vaccinated animals.In this paper, we describe the development and correlation of two techniques for the detection and quantification of the JDV load in plasma: the quantification of virus RNA and the quantification of virus antigen by enzyme-linked immunosorbent assay (ELISA). The quantification of circulating viral RNA is a widely accepted method for monitoring the levels of human immunodeficiency virus (HIV) RNA, and the quantity of circulati...

show abstract

“…In the present study, antibodydependent enhancement was an infrequent finding. This is probably due to our assay conditions (for example, the use of an NCS control for each immune serum dilution may have reduced possible artifacts due to nonspecific effects of sera on virus replication [19,58]), as well as to the stringent criterion adopted to define an increase of FIV replication as enhancement (Նtwofold increase of RT production). Although enhancement is often seen at subneutralizing concentrations of test sera (49), we exclude the possibility that our immune sera were tested too concentrated to observe the phenomenon, since on repeated occasions they were diluted further with no evidence of more frequent or potent enhancement (data not shown).…”

Section: Discussionmentioning

confidence: 99%

Autologous and Heterologous Neutralization Analyses of Primary Feline Immunodeficiency Virus Isolates

Mauro

Matteucci

Giannecchini

et al. 1998

J Virol

View full text Add to dashboard Cite

Feline immunodeficiency virus (FIV) provides a model system with which the significance of neutralizing antibody (NA) in immunosuppressive lentivirus infections may be studied. To date, no detailed analysis of the neutralization properties of primary FIV isolates has been reported. In this study, we have conducted the first comprehensive study of the sensitivity to autologous and heterologous neutralization in a lymphoid cell-based assay of 15 primary FIV isolates and, for comparison, of one tissue culture-adapted strain. Primary isolates in general proved highly NA resistant, although there was considerable individual variation. Variation was also observed in the capacity of immune sera to neutralize heterologous FIV isolates. The ability of sera to neutralize isolates or for isolates to be neutralized by sera did not correlate with epidemiological and genetic relatedness or with the quasispecies complexity of the isolates. From the study of specific-pathogen-free cats experimentally infected with viral isolates associated with NA of different breadths, it appears that the development of FIV vaccines cannot rely on the existence of viral strains inherently capable of inducing especially broad NA responses.

show abstract

Human plasma enhances the infectivity of primary human immunodeficiency virus type 1 isolates in peripheral blood mononuclear cells and monocyte-derived macrophages

Cited by 32 publications

References 43 publications

Vaccine-induced enhancement of viral infections

Vaccine-induced enhancement of viral infections

TaqMan Real-Time Reverse Transcription-PCR and JDVp26 Antigen Capture Enzyme-Linked Immunosorbent Assay To Quantify Jembrana Disease Virus Load during the Acute Phase of In Vivo Infection

Autologous and Heterologous Neutralization Analyses of Primary Feline Immunodeficiency Virus Isolates

Contact Info

Product

Resources

About